Fundz

Mogrify Extends Series A Financing To $46 Million Usd

PRIVATEOct 02, 2023

Round Type

Series A

CambridgeBiotechnology

Description

Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

Quick answer

Mogrify raised an undisclosed amount in a Series A round, dated October 2, 2023. Mogrify is based in Cambridge, Maryland, United States.

How much did Mogrify raise?
Mogrify raised an undisclosed amount in a Series A round on October 2, 2023.
What does Mogrify do?
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell..
Where is Mogrify based and how big is it?
Mogrify is based in Cambridge, Maryland, United States.
Who are the decision-makers at Mogrify?
Fundz holds 1 contact at Mogrify. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Mogrify that raised within 45 days of this round, from Fundz verified event records.

  • On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
  • Greenbrook TMS raised $2.5M (Seed) on November 16, 2023.
  • Proxima Fusion raised an undisclosed amount (Pre-Seed) on November 16, 2023.
  • Nature's Toolbox raised $48M (Series B) on November 16, 2023.
  • Route 92 Medical raised $31M (Series F) on November 16, 2023.
  • Bone Biologics raised $729K (Seed) on November 16, 2023.

Who to call at Mogrify, and when

A new round usually means Mogrify is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Mogrify raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Mogrify, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Mogrify. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Mogrify

Location

Cambridge, Maryland, United States

About

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Mogrify raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Mogrify's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Mogrify raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.